Lisa Delfini Sells 4,350 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CFO Lisa Delfini sold 4,350 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $2.64, for a total transaction of $11,484.00. Following the transaction, the chief financial officer now directly owns 53,279 shares in the company, valued at $140,656.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Trevi Therapeutics Trading Down 1.6 %

Shares of Trevi Therapeutics stock opened at $2.50 on Monday. Trevi Therapeutics, Inc. has a 12-month low of $0.97 and a 12-month high of $4.00. The firm’s 50-day moving average price is $2.97 and its two-hundred day moving average price is $2.15.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). Equities research analysts anticipate that Trevi Therapeutics, Inc. will post -0.42 EPS for the current year.

Institutional Investors Weigh In On Trevi Therapeutics

A number of large investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD acquired a new stake in Trevi Therapeutics during the first quarter worth about $47,000. Silverarc Capital Management LLC boosted its stake in shares of Trevi Therapeutics by 4.7% in the 3rd quarter. Silverarc Capital Management LLC now owns 927,415 shares of the company’s stock valued at $2,022,000 after purchasing an additional 41,491 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after purchasing an additional 60,249 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new stake in shares of Trevi Therapeutics in the 1st quarter valued at approximately $208,000. Finally, SG Americas Securities LLC boosted its stake in shares of Trevi Therapeutics by 401.4% in the 4th quarter. SG Americas Securities LLC now owns 98,253 shares of the company’s stock valued at $132,000 after purchasing an additional 78,656 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TRVI has been the topic of a number of recent research reports. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price target on shares of Trevi Therapeutics in a research report on Thursday, March 21st. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price target on shares of Trevi Therapeutics in a research report on Wednesday, May 8th.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.